FiftyBidsGovernment contracts and grants, in one plain-English search.

Back to search

Forecast

Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to continue to support the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium, which coordinates research on prevention, diagnosis, treatment, and mechanisms of resistance in SCLC.

FromNational Institutes of Health
Who can applystate governments, counties, cities and townships, special districts (water, fire, parks, etc.), school districts, public colleges and universities and 9 more types
Eligibility notesOther Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S.
How muchAmount not stated
DeadlineMon, Jan 25, 2027 (estimated) (94 days left)
CategoryHealth
TypeCooperative agreement
Opportunity #PAR-27-009
Assistance listing93.393, 93.394, 93.395, 93.396
PostedTue, Mar 24, 2026

Heads-up: Forecast: not open yet. Dates and amounts are the agency's estimates.

Open the official posting

From the notice

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to continue to support the Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium, which coordinates research on prevention, diagnosis, treatment, and mechanisms of resistance in SCLC. The CC manages administrative activities, centralized databases, tissue banking and a virtual biospecimen resource, biostatistics and bioinformatics support, in vivo and in vitro model repositories, and communications and website operations for the Consortium. Since its establishment in response to the Recalcitrant Cancer Research Act, the Consortium has catalyzed SCLC-focused research and enabled major advances in molecular characterization, tumor heterogeneity, microenvironment and immune evasion, biomarker development, preclinical models, therapeutic strategies, and clinical translation. The current U24 CC, based at Sloan Kettering with collaborating institutions, organizes meetings, maintains extensive -omics and model resources, supports young investigators, and provides datasets and models to the research community. The reissue NOFO will support a five-year cooperative agreement to sustain these shared resources and collaborations. This is a Forecast for a single source that will invite application(s) from eligible organization(s) to apply. Please see the Eligibility Section for additional information. In accordance with NIH standard peer-review processes, the application(s) w

We may have shortened this. The official posting is the record. We are not affiliated with the agency that published it.